Real-World Mapping Antithrombotic Regimens in MM Patients on Treatment
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorGruppo Italiano Malattie EMatologiche dell'Adulto
About this trial
The goal of this observational study is to learn about antithrombotic regimens in Multiple myeloma patients. The main question it aims to answer is the efficacy of different types of thromboprophylaxis (antiplatelet agents, heparins, oral anticoagulants) in preventing venous thromboembolism (VTE).
Eligibility criteria
Qualifiers
Age equal to or greater than 18 years of age.
New diagnosis of symptomatic MM according to the CRAB or the SLIM criteria of the International Myeloma Working Group
First active treatment for MM started after recruitment in the study
Signed informed consent
Disqualifiers
Patients having had thrombosis within 6 months before diagnosis of MM
Patients with need of combined antithrombotic regimens (i.e. VKA or DOAC or LMWK and one or two antiplatelet drugs)
Ongoing first active treatment for MM initiated before the starting of the study.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov